Por: The Boston Globe Business July 24, 2023
Roche Holding AG will work together with Alnylam Pharmaceuticals Inc. on a potential treatment for high blood pressure in a deal worth as much as $2.8 billion, expanding the Swiss company’s footprint beyond the cancer therapies that long anchored its business.Roche will pay Cambridge-based Alnylam $310 million in cash upfront, together with development, regulatory and sales milestones, the companies said in statements on Monday. If they’re... + full article
MarketWatch USA Business October 23, 2023
The acquisition will give Roche rights over Telavant's drug candidate that has shown promise for inflammatory bowel disease and could have potential in other indications, it said. Roche will have rights to commercialize the drug in the U.S. and Japan, pending clinical-trial... + más
After ‘transformative’ year, Roivant aims to challenge bigger rivals in inflammation and immunology | MarketWatch
Republican Presidential Candidate Vivek Ramaswamy Sells $32 Million Of Biotech Firm’s Stock | Forbes
MarketWatch USA Business October 09, 2023
Alnylam said in a Monday morning that the FDA had not been satisfied by the clinical meaningfulness of the drug’s efficacy. An approval in the cardiomyopathy indication could have meant a significant boost to Alnylam sales, which were $1 billion in 2022. Far more patients... + más
Alnylam signs $2.8 billion deal with Roche to advance Cambridge biotech’s injection for high blood pressure | The Boston Globe
Alnylam deploys gene-silencing in early study aimed at subduing Alzheimer’s | The Boston Globe
The Boston Globe USA Business July 24, 2023
Alnylam Pharmaceuticals will receive $310 million in cash from the Swiss drug giant Roche Holding AG and be eligible for as much as $2.5 billion more in a deal to jointly develop and market the Cambridge biotech’s novel potential treatment for high blood pressure.The firms... + más
Alnylam’s experimental Alzheimer’s drug shows benefits in patients for six months | The Boston Globe
Alnylam halts work on eye drug, citing new US law over pricing | The Boston Globe
The Boston Globe USA Business July 17, 2023
Alzheimer’s patients who received a single dose of an experimental gene-silencing treatment from Alnylam Pharmaceuticals showed benefits for six months in a small study, the Cambridge biotech said Monday.Alnylam reported in April that recipients of the medicine experienced... + más
The Boston Globe USA Business April 26, 2023
Cambridge scientists are deploying a novel gene-silencing technology used against ultra-rare diseases in a new effort to subdue Alzheimer’s, the memory-raving disorder that afflicts tens of millions of people worldwide.In findings reported Wednesday afternoon, Alnylam... + más
Reimagining Alzheimer’s (Part 8): APOE4 Removal Reduces Symptoms Of Alzheimer’s Disease | Forbes
Orlando Sentinel USA Sports March 25, 2023
Orangewood Christian 11, The Master’s Academy 1 Buzz: Austin Waring threw 5 innings of 1-run ball (0 earned runs) while allowing 4 hits and striking out 8 for Orangewood Christian. He lowered his season ERA to 0.78. Aiden McKee went 3-for-3 with a double, a walk, an RBI and a... + más
NFL Playoff Scenarios | ABC News
Le Krewe du Roi celebrates the state at 58th annual Mardi Gras Ball | The Advocate
The Boston Globe USA Business October 27, 2022
Alnylam Pharmaceuticals Inc. said it’s stopping work on a treatment for a rare eye disease because of a new US drug-pricing law with the potential to limit how much it could charge for the medication in the future.Alnylam will not begin a planned late-stage trial of its drug... + más
ALNY Reiterates Guidance, TVTX Loss Widens, DXCM Paints Rosy Outlook | RTTNews
Halted Stocks | Forbes
About iurex | Privacy Policy | Disclaimer |